This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Nivolumab and relatlimab for untreated advanced or metastatic melanoma – first line

< Back

Nivolumab and relatlimab for untreated advanced or metastatic melanoma – first line


Cancer and Palliative Care

August 2019

A fixed dose combination of nivolumab and relatlimab is in development for the treatment of advanced and metastatic melanoma patients that have not received previous treatment. Melanoma is a cancer of the skin, when is advanced or metastatic, the cancer has spread to other organs and tissues such as lymph nodes and the brain. Metastatic melanoma can present a range of different symptoms including lumps under the skin, swollen lymph nodes, bone pain and headaches. At this stage the cancer can’t be cured.
Nivolumab works by improving the activity of white blood cells increasing the ability of the immune system to kill cancer cells. Relatlimab has the potential to increase the immune system response and kill cancer cells. If licenced for this indication, a fixed dose combination of intravenous nivolumab and relatlimab may provide a new therapeutic option for untreated patients that shows similar adverse effects than treatment with nivolumab alone.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article


Connect to the Innovation Observatory


Load More Related Posts

Get Alerts